Chitosan Core-Shell Nanoparticles for Layered Vaccine Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine delivery systems and adjuvants are limited in effectively directing immune responses, particularly for pathogens like malaria, tuberculosis, and HIV, and lack suitable alternatives to enhance vaccine efficacy and accessibility, especially in populations with reduced immune responses.
Innovation Solution
Crosslinked cationic chitosan nanoparticles with a core-shell structure, such as N-trimethyl chitosan and tripolyphosphate, are used to create a layer-by-layer delivery system for active agents, providing controlled release and enhanced immune stimulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional adjuvants and delivery systems are used, then existing vaccines can be administered, but the immune response is insufficient for sophisticated pathogens like malaria, tuberculosis, and HIV
Solution Approach 1:
The patent employs composite nanoparticle structures combining chitosan (cationic polymer) with various anionic polymers (polyacrylic acid, polyacrylamide, polyvinyl alcohol, or carboxymethyl cellulose) to create core-shell nanoparticles. This composite approach enables the delivery system to adapt to different pathogens and antigens while maintaining effective immune stimulation, resolving the contradiction between vaccine efficacy and adaptability to sophisticated pathogens.
Solution Approach 2:
The patent systematically varies multiple parameters including polymer ratio (1:1 to 10:1), nanoparticle size (50-500 nm), and polymer composition to optimize delivery performance. By changing these parameters, the system can adapt to different pathogen characteristics and achieve effective immune responses for sophisticated pathogens that require tailored delivery approaches.
2Reliability
If existing delivery systems are used, then vaccines can be delivered, but the ability to direct immune responses is limited
Solution Approach 1:
The patent segments the delivery system into distinct functional components: a cationic chitosan core that provides structural framework and antigen loading capacity, and an anionic polymer shell that controls release and enhances immune stimulation. This segmentation allows each component to be optimized independently for its specific function while working synergistically to achieve effective immune response direction.
Solution Approach 2:
The nanoparticle formulation acts as an intermediary between the vaccine antigen and the immune system. The chitosan-anionic polymer composite structure serves as a mediator that facilitates controlled antigen release and enhances immunogenicity, enabling effective immune response direction without requiring complex external delivery systems.
3Reliability
If more adjuvants and delivery systems are developed, then vaccine effectiveness can be improved, but the number of approved systems remains limited
Solution Approach 1:
The chitosan-based nanoparticle system utilizes the inherent properties of chitosan (natural polymer, biocompatibility, cationic charge) to provide adjuvant activity and antigen delivery without requiring extensive external modification. The system leverages the self-assembling capability of chitosan with anionic polymers to form stable nanoparticles, simplifying manufacturing and potentially facilitating regulatory approval by reducing the need for complex synthesis procedures.
4Reliability
If biocompatible and biodegradable polymer nanoparticles are used, then antigen stability and cell uptake are enhanced, but the delivery system must be carefully designed
Solution Approach 1:
The patent applies local quality by creating a core-shell structure where the inner chitosan core provides antigen loading and stability, while the outer anionic polymer shell provides controlled release and immune stimulation. Each layer has specific functional properties optimized for its location within the nanoparticle, enabling enhanced antigen stability and cell uptake without requiring overly complex overall system design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system induces potent and long-lasting immune responses, demonstrating improved vaccine efficacy and safety for diseases like malaria, with potential for mucosal and intramuscular delivery.
Implementation Method 1
configured to allow layer-by-layer delivery of one or more active agents in a controlled fashion
Implementation Method 2
nanoparticles having a core-shell structure
Implementation Method 3
crosslinked polymer comprising a cationic chitosan and an anionic cross-linker
Data Source
AI summary
Provided herein are pharmaceutical compositions comprising chitosan based nanoparticles, such as those having a core-shell structure, which can be configured for layer-by-layer delivery of active agent(s).